Sudden vision loss claims

Patients report sudden, irreversible vision damage after using GLP-1 weight-loss drugs.

“The lawsuits claim Novo Nordisk and Eli Lilly should have warned consumers about vision loss as a potential side effect.”

Lawsuits targeting drugmakers

Over 100 lawsuits filed in New Jersey since 2025 allege GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy.

Drug companies deny link

Novo Nordisk and Eli Lilly state there is no causal relationship between GLP-1s and vision loss.

“A causal relationship between GLP-1RAs, including semaglutide, and NAION cannot be confirmed based on the totality of data”

NAION explained

Non-arteritic anterior ischemic optic neuropathy causes sudden, painless vision loss in people 50 and older.

Global warnings differ

Some countries require GLP-1 drugs to list vision loss as a rare side effect, while the US does not.

Clinical trial findings

Recent studies show no increased risk of NAION in patients using Wegovy or Ozempic in clinical trials.

Regulatory actions

European Medicines Agency recommended adding NAION warnings to Novo Nordisk's weight-loss drugs in 2025.

Drug safety focus

Novo Nordisk emphasizes patient safety as a top priority while fighting the lawsuits.

Ophthalmic concerns

NAION affects 2 to 10 people per 100,000 in the US and causes blurred vision or partial blindness.

Legal action details

Law firms in New Jersey have filed lawsuits on behalf of patients claiming GLP-1 drugs caused vision loss.